Device Stakeholders Debate Whether FDA Can, Or Should, Revoke 510(k)s
This article was originally published in The Gray Sheet
Executive Summary
FDA should have no reason to rescind 510(k) substantial equivalence decisions for marketed devices except in extreme cases of fraud, device industry lobbyists said in recent comments to FDA
You may also be interested in...
CDRH Drops Seven Divisive 510(k) Proposals; Congress Picks Some Up
The device center is dropping seven controversial 510(k) reform-related proposals, including creating a “class IIb” category of devices, following pushback from industry. But some of the matters are under consideration on Capitol Hill.
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.